<DOC>
	<DOCNO>NCT00004113</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy temozolomide patient recurrent malignant glioma . II . Determine radiographic response regimen patient . III . Determine time tumor progression patient regimen . IV . Determine quality life patient . OUTLINE : Patients receive oral temozolomide daily 42 day . Courses repeat every 70 day 1 year absence disease progression unacceptable toxicity . Quality life assess every 1-2 month . Patients follow every 3-4 month . PROJECTED ACCRUAL : A total 20-35 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent malignant glioma , include : Glioblastoma Gliosarcoma High grade glioma Anaplastic astrocytoma Anaplastic mixed oligoastrocytoma Anaplastic oligodendroglioma Must evidence tumor recurrence progression gadolinium enhance MRI CT scan follow radiotherapy without chemotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 3 time ULN Alkaline phosphatase less 2 time ULN Renal : Creatinine le 1.5 time ULN BUN less 1.5 time ULN Other : No nonmalignant systemic disease would cause patient poor medical risk No acute infection require intravenous antibiotic No psychological disorder would interfere study compliance HIV negative No AIDSrelated illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No frequent vomit medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction ) No prior concurrent malignancy , except : Surgically cure carcinoma situ cervix Basal squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy At least 4 week since prior biologic therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No prior temozolomide dacarbazine Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior external beam radiotherapy At least 8 week since prior stereotactic radiosurgery Surgery : At least 2 week since prior brain biopsy , craniotomy , surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>